SCHEMBL85578

SCHEMBL85578

O=c1ccccn1-c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 1/20 0.54
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
MAPT P10636 5/20 0.48
RAB9A P51151 3/20 0.48
HTT P42858 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
POLB P06746 2/20 0.47
PLEC Q15149 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
RECQL P46063 1/20 0.47
MCL1 Q07820 1/20 0.47
KAT2B Q92831 1/20 0.45
NPC1 O15118 2/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18755231 0.77 F10 (0.40) LMNAALDH1A1MAPTHTTCYP1A2
SCHEMBL27693543 0.77 CYP3A4 (0.42) SCN2ALMNAALDH1A1MEN1KMT2A
SCHEMBL6535629 0.77 TSHR (0.50) SCN2AALDH1A1MEN1KMT2AMAPT
SCHEMBL85643 0.77 MEN1 (0.52) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL1882326 0.76 ALDH1A1 (0.53) SCN2ALMNAALDH1A1MEN1KMT2A
SCHEMBL2240147 0.76 SCN2A (0.56) SCN2ALMNAALDH1A1MEN1KMT2A
SCHEMBL3078101 0.76 KAT2B (0.48) SCN2AALDH1A1MEN1KMT2AMAPT
SCHEMBL3833661 0.76 NPC1 (0.47) SCN2AALDH1A1MEN1KMT2AMAPT
SCHEMBL5945870 0.76 SMN1; SMN2 (0.48) SCN2ALMNAALDH1A1MEN1KMT2A
SCHEMBL31463590 0.76 L3MBTL1 (0.40) LMNAALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514348-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) Noetix Pharma LLC (US) 2025-03-05 EP claimed
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC 2024-09-12 US claimed
WO-2023211684-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC (US) 2023-11-02 WO claimed
EP-0866656-B1 USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS MARGOLIN SOLOMON B (US) 2007-04-25 EP claimed
EP-1261338-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2006-06-14 EP claimed
EP-1069898-B1 TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS MARGOLIN SOLOMON B (US) 2004-05-12 EP claimed
EP-0813409-B1 TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS MARGOLIN SOLOMON B (US) 2004-05-06 EP claimed
EP-1261338-A4 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2004-05-06 EP claimed
EP-1261338-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY Cymar, Inc. (US) 2002-12-04 EP claimed
WO-2001062253-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR, INC. (US) 2001-08-30 WO claimed
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC (US) 2025-12-04 US disclosed
US-20250114376-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC. 2025-04-10 US disclosed
EP-4514348-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) Noetix Pharma LLC (US) 2025-03-05 EP disclosed
US-12226407-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (US) 2025-02-18 US disclosed
EP-4491180-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF Avalyn Pharma Inc. (US) 2025-01-15 EP disclosed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US disclosed
US-4057547-A CNS DEPRESSANT, CARDIOVASCULAR ORTHO PHARMACEUTICAL CORPORATION (US) 1977-11-08 US disclosed
US-4052509-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-10-04 US disclosed
US-4042699-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-08-16 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) CHAT, PNPO, PLPBP SCN2A 3090/4885LMNA 1302/4885ALDH1A1 1343/4885
US-20250114376-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK SCN2A 2606/4885LMNA 2204/4885ALDH1A1 167/4885
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK SCN2A 2606/4885LMNA 2204/4885ALDH1A1 167/4885
US-12226407-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof PLPBP, PIR, PDXK SCN2A 2606/4885LMNA 2204/4885ALDH1A1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.